vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $47.3M, roughly 1.2× CIVISTA BANCSHARES, INC.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs -83.0%, a 114.7% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 11.3%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CIVB vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.3M | $57.3M |
| Net Profit | $15.0M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 31.7% | -83.0% |
| Revenue YoY | — | 36.9% |
| Net Profit YoY | 47.4% | -9.6% |
| EPS (diluted) | $0.72 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $57.3M | ||
| Q3 25 | $44.2M | $51.3M | ||
| Q2 25 | $41.4M | $48.5M | ||
| Q1 25 | $40.6M | $32.7M | ||
| Q4 24 | $40.4M | $41.8M | ||
| Q3 24 | $39.3M | $33.3M | ||
| Q2 24 | $38.1M | $29.1M |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $12.8M | $-52.9M | ||
| Q2 25 | $11.0M | $-46.6M | ||
| Q1 25 | $10.2M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $8.4M | $-43.6M | ||
| Q2 24 | $7.1M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | -82.2% | ||
| Q3 25 | 35.4% | -102.6% | ||
| Q2 25 | 31.1% | -93.4% | ||
| Q1 25 | 29.4% | -143.7% | ||
| Q4 24 | 28.2% | -98.6% | ||
| Q3 24 | 25.2% | -132.0% | ||
| Q2 24 | 21.2% | -139.2% |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | 28.9% | -103.1% | ||
| Q2 25 | 26.6% | -96.1% | ||
| Q1 25 | 25.0% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 21.3% | -131.2% | ||
| Q2 24 | 18.5% | -110.9% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | $-0.73 | ||
| Q3 25 | $0.68 | $-0.82 | ||
| Q2 25 | $0.71 | $-0.75 | ||
| Q1 25 | $0.66 | $-0.81 | ||
| Q4 24 | $0.62 | $-0.71 | ||
| Q3 24 | $0.53 | $-0.73 | ||
| Q2 24 | $0.45 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $553.9M | $139.1M |
| Total Assets | $4.3B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $139.1M | ||
| Q3 25 | $499.0M | $148.8M | ||
| Q2 25 | $404.1M | $-11.9M | ||
| Q1 25 | $397.4M | $18.9M | ||
| Q4 24 | $388.5M | $21.7M | ||
| Q3 24 | $394.4M | $11.2M | ||
| Q2 24 | $373.8M | $39.3M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $480.2M | ||
| Q3 25 | $4.1B | $506.9M | ||
| Q2 25 | $4.2B | $372.7M | ||
| Q1 25 | $4.1B | $386.7M | ||
| Q4 24 | $4.1B | $392.3M | ||
| Q3 24 | $4.1B | $363.6M | ||
| Q2 24 | $4.0B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $-25.4M | ||
| Q3 25 | $19.0M | $-26.6M | ||
| Q2 25 | $11.1M | $-23.3M | ||
| Q1 25 | $3.6M | $-40.4M | ||
| Q4 24 | $48.2M | $-18.8M | ||
| Q3 24 | $12.9M | $-25.2M | ||
| Q2 24 | $12.2M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $3.5M | — | ||
| Q4 24 | $44.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 8.5% | — | ||
| Q4 24 | 109.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
RYTM
Segment breakdown not available.
